PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase

Author:

Kwong Yok-Lam1ORCID,Chan Thomas S. Y.1,Tan Daryl23,Kim Seok Jin4,Poon Li-Mei5,Mow Benjamin6,Khong Pek-Lan7,Loong Florence8,Au-Yeung Rex8,Iqbal Jabed9,Phipps Colin23,Tse Eric1

Affiliation:

1. Department of Medicine, Queen Mary Hospital, Hong Kong;

2. Raffles Cancer Center, Raffles Hospital, Singapore;

3. Department of Haematology, Singapore General Hospital, Singapore;

4. Division of Haematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea;

5. Department of Hematology/Oncology, National University Cancer Institute, Singapore;

6. Mow Blood and Cancer Clinic, Mount Elizabeth Medical Center, Singapore;

7. Department of Diagnostic Radiology, and

8. Department of Pathology, Queen Mary Hospital, Hong Kong; and

9. Department of Anatomic Pathology, Singapore General Hospital, Singapore

Abstract

Key Points NK/T-cell lymphomas failing L-asparaginse, generally fatal, showed a high CR rate to PD1 blockade with pembrolizumab. Comprehensive clinical, radiologic, pathologic, and molecular assessments showed different patterns of CRs and PRs.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3